Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

A 12-Week Efficacy Study of Paracetamol 1000mg Sustained-release Tablets in Patients With Osteoarthritis

ClinicalTrials.gov ID: NCT02311881

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT02311881. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 2:32 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Efficacy and Safety Study of Sustained-release Paracetamol in Subjects With Osteoarthritis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of the study is to determine whether paracetamol 1000 mg sustained-release (SR) tablets administered orally, twice daily are effective and safe in the treatment of patients with osteoarthritis of the knee or hip.

Study identification

NCT ID
NCT02311881
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
960 participants

Conditions and interventions

Eligibility (public fields only)

Age range
40 Years to 80 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 2015 (Type not available)
Primary completion
Feb 2016 (Actual)
Completion
Feb 2016 (Actual)
Last update posted
Apr 7, 2017

2015 – 2016

United States locations

U.S. sites
56
U.S. states
20
U.S. cities
49
Facility City State ZIP Site status
GSK Investigational Site Birmingham Alabama 35242 —
GSK Investigational Site Huntsville Alabama 35801 —
GSK Investigational Site Chandler Arizona 85224 —
GSK Investigational Site Tucson Arizona 85712 —
GSK Investigational Site Tucson Arizona 85745 —
GSK Investigational Site Anaheim California 92801 —
GSK Investigational Site Carmichael California 95608 —
GSK Investigational Site Fresno California 93702 —
GSK Investigational Site North Hollywood California 91606-1559 —
GSK Investigational Site San Diego California 92103 —
GSK Investigational Site Brandon Florida 33511 —
GSK Investigational Site Clearwater Florida 33756 —
GSK Investigational Site Edgewater Florida 32132 —
GSK Investigational Site Hialeah Florida 33012 —
GSK Investigational Site Hialeah Florida 33016 —
GSK Investigational Site Homestead Florida 33030 —
GSK Investigational Site Jupiter Florida 33458 —
GSK Investigational Site Miami Florida 33155 —
GSK Investigational Site Miami Florida 33173 —
GSK Investigational Site Miami Florida 33185 —
GSK Investigational Site Oldsmar Florida 34677 —
GSK Investigational Site Orlando Florida 32806 —
GSK Investigational Site Oviedo Florida 32765 —
GSK Investigational Site Port Orange Florida 32127 —
GSK Investigational Site South Miami Florida 33143 —
GSK Investigational Site West Palm Beach Florida 33409 —
GSK Investigational Site Savannah Georgia 31406 —
GSK Investigational Site Chicago Illinois 60640 —
GSK Investigational Site Evanston Illinois 60201 —
GSK Investigational Site Prairie Village Kansas 66206 —
GSK Investigational Site Wichita Kansas 67203 —
GSK Investigational Site Crestview Hills Kentucky 41017 —
GSK Investigational Site New Orleans Louisiana 70115 —
GSK Investigational Site Watertown Massachusetts 02472 —
GSK Investigational Site St Louis Missouri 63139 —
GSK Investigational Site Bellevue Nebraska 68005 —
GSK Investigational Site Omaha Nebraska 68134 —
GSK Investigational Site Las Vegas Nevada 89119 —
GSK Investigational Site Brooklyn New York 11230 —
GSK Investigational Site Buffalo New York 14223 —
GSK Investigational Site Hartsdale New York — —
GSK Investigational Site Hickory North Carolina 28601 —
GSK Investigational Site Cincinnati Ohio 45227 —
GSK Investigational Site Cincinnati Ohio 45242 —
GSK Investigational Site Cincinnati Ohio 45255 —
GSK Investigational Site Dayton Ohio 45424 —
GSK Investigational Site Toledo Ohio 43623 —
GSK Investigational Site Oklahoma City Oklahoma 73119 —
GSK Investigational Site Altoona Pennsylvania 16602 —
GSK Investigational Site Duncansville Pennsylvania 16635 —
GSK Investigational Site Smithfield Pennsylvania 15478 —
GSK Investigational Site Mt. Pleasant South Carolina 29464 —
GSK Investigational Site Dallas Texas 75230 —
GSK Investigational Site Plano Texas 75075 —
GSK Investigational Site San Antonio Texas 78209 —
GSK Investigational Site San Antonio Texas 78229 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02311881, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 7, 2017 · Synced Nov 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.